Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis, 2017

  • ID: 4435232
  • Report
  • 137 pages
  • P&S Market Research
1 of 3
WNT Signaling Pathway Inhibitors Pipeline in 2017

The study analyzed that the Wnt signaling pathway inhibitors therapeutics pipeline comprises approximately 26 drug candidates in different stages of development. Wnt or ß-Catenin signaling pathway plays an important role in the development of pluripotent cells. The signaling pathway was earlier named as Wingless (Wng) in Drosophila and Int1 in the mouse. Wnt proteins consist of several glycoproteins that have conserved cysteine residues. There are 19 human Wnt genes that encode spliced isoforms. Wnt proteins bind to the Frizzled (Fz) receptors which forms the complex with low-density lipoprotein receptor-related protein (LRP).

Insights on Pipeline Segments:

According to the research findings, most of the drug candidates of the Wnt signaling pathway inhibitors are being developed as the small molecule. According to the Center for Disease Control and Prevention (CDC), more than 1.5 million cases of invasive cancer, including about 15,000 cases among children younger than 20 years, and more than 590,000 deaths from cancer, are reported every year in the U.S. The rising prevalence of cancer is a major factor driving the pipeline, since Wnt signaling pathway has been recognized in the development of cancer cells.

Positive Clinical Results of WNT Signaling Pathway Inhibitors Therapeutics Candidates:

The positive clinical results of Wnt signaling pathway inhibitors drug candidates are driving the pipeline growth. Samumed, LLC announced the successful completion of a 52-week Phase II clinical trial of its potential treatment for osteoarthritis of the knee. SM04690 is a novel, small molecule inhibitor of the Wnt signaling pathway, administered as an intra-articular injection. SM04690 appeared to be safe and well-tolerated at all dose levels studied.

Various Collaborations for Wnt Signaling Pathway Inhibitors Therapeutics Drug Development:

In July 2017, Oncology Venture AB and 2X Oncology, Inc. entered into an exclusive global license agreement with Eisai Inc. for Eisai's Phase II PARP inhibitor E7449 - now called 2X-121. 2X-121 would be developed by 2X Oncology, Inc., a precision medicine company developing targeted therapeutics to address significant unmet needs in women's cancer.

Some of the key players developing drugs for the treatment of Wnt signaling pathway inhibitors therapeutics include Samumed, LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics, Inc. and others.

WNT Signaling Pathway Inhibitors Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

5. Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology5.3 Phase I: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Investigational New Drug Application (IND): Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Pre-Clinical: Drug profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Clinical Trials
5.5.4 Clinical Results
5.5.5 Strategic Development
5.5.6 Designation
5.5.7 Grants
5.5.8 Patent
5.5.9 Technology
5.6 Discovery: Drug profiles
5.6.1 Pre-Clinical Study
5.6.2 Pre-Clinical Results
5.6.3 Strategic Development
5.6.4 Designation
5.6.5 Grants
5.6.6 Patent
5.6.7 Technology
5.7 Unknown Phase: Drug profiles
5.7.1 Clinical trial
5.7.2 Strategic Development
5.7.3 Designation
5.7.4 Grants
5.7.5 Patent
5.7.6 Technology
5.8 Inactive Drugs

6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Wnt Signaling PAThway Inhibitors Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Wnt Signaling PAThway Inhibitors Therapeutics Pipeline

7. Competitive Landscape
7.1 Key Players Benchmarking for Wnt Signaling PAThway Inhibitors Therapeutics Pipeline
7.2 SWOT Analysis of Wnt Signaling PAThway Inhibitors Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables:

Pipeline Analysis Of Wnt Signaling Pathway Therapeutics, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Ind Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Description Of Unknown Drug Candidates
Clinical Trials Of Unknown Drug Candidates
Companies - At A Glance

List of Figures:

Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
WNT Signaling Pathway Inhibitors Therapeutics Drug Candidates Under Development (2017)
WNT Signaling Pathway Inhibitors Therapeutics Pipeline Split, By Molecule Type (2017)
WNT Signaling Pathway Inhibitors Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll